RecruitingOBSERVATIONAL

Ex VIvo DEtermiNed Cancer Therapy

The EVIDENT study aims to discover if testing a sample of your tumour in the lab can predict how effective standard cancer treatments will be for you. If you have a solid cancer, such as bladder cancer, kidney cancer, melanoma, sarcoma, glioblastoma, or head and neck cancer, and are having surgery or a biopsy, you might be able to take part. Researchers will take a small piece of your tumour and test it with different medications to see how it reacts. They will then compare these lab results with how your cancer actually responds to treatment to understand if this test can accurately tell us what to expect. This could help doctors choose the best treatments for patients in the future.

At a glance

Status

Recruiting

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Enrolment target

600

Start

07 Jul 2021

Estimated completion

01 Jan 2027

Bladder Cancer Kidney Cancer Melanoma Sarcoma Glioblastoma Head and Neck Cancer

What is this study about?

The EVIDENT study is looking into a new way to understand how your cancer might react to treatment. Imagine your doctor could take a small piece of your tumour and test it with different medicines in the lab before you even start treatment. This study wants to see if that's possible and if it can accurately predict whether standard cancer treatments, like chemotherapy or targeted therapies, will work well for you.

Researchers are collecting tiny samples of tumours from patients who are already having surgery, a biopsy, or a fluid sample taken for their diagnosis. They then test these samples with various existing cancer drugs, and even some newer ones still in development. The goal is to see which treatments make the cancer cells shrink or die in the lab.

Afterwards, for those patients who go on to receive treatment, the study will compare these lab results with how the patient's cancer actually responds. This will help the researchers find out how good this lab test is at telling us what will happen in real life. If successful, this could one day help doctors choose the most effective treatments for patients sooner.

Key takeaways

Tests tumour samples in the lab to predict treatment response.
Aims to improve how doctors choose cancer treatments in the future.
Participants donate a small tumour sample during a planned procedure.
No change to your current treatment based on study results.
Open to patients with several types of solid cancer, aged 16 and over.

Who may be eligible?

You might be able to take part in this study if you are 16 years old or older and have been diagnosed with, or are suspected of having, a solid cancer. This includes cancers like bladder cancer, kidney cancer, melanoma, sarcoma, glioblastoma, or head and neck cancer.

To join, you need to be having surgery, a biopsy, or a fluid sample taken where an extra small piece of your tumour can be collected. You also need to agree to give a small blood sample and provide your written permission to participate. It's okay if you've already had cancer treatment in the past, even if your cancer has come back or didn't respond to previous therapies.

However, you cannot join if you currently have hepatitis B, hepatitis C, or HIV, as the labs aren't set up to safely handle these. You also can't take part if you currently have a COVID-19 infection.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 16 years old or older?
Do you have a solid cancer (e.g., bladder, kidney, melanoma)?
Are you having surgery, a biopsy, or a fluid sample taken for your cancer?
Are you able to provide a small blood sample?
Do you not have active Hepatitis B, Hepatitis C, HIV, or COVID-19?

Answer every question to see your result.

What does participation involve?

If you decide to take part in the EVIDENT study, it will involve donating a small piece of your tumour tissue. This sample will be taken during a procedure you are already having, such as surgery, a biopsy, or when fluid is removed from your tumour. This means no extra procedures are needed just for the study. You will also be asked to provide a single 9ml blood sample. The research team will then follow your medical progress to see how your cancer responds to your ongoing standard treatments. The total duration of your participation will depend on your treatment journey.

Potential risks and benefits

A potential benefit of joining this study is helping researchers understand how to better predict cancer treatment responses, which could lead to more effective treatments for future patients. For you, there are no direct benefits to your current treatment as the results from the lab tests won't guide your immediate care. The main risk involves the usual small risks associated with having a blood test. You are completely free to withdraw from the study at any time without giving a reason, and this will not affect your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Sheffield Teaching Hospitals NHS Foundation Trust
Verified postcode
Sheffield, United Kingdom· Recruiting

Common questions

What kind of cancer can join this study?

This study is for people with solid cancers such as bladder cancer, kidney cancer, melanoma, sarcoma, glioblastoma, and head and neck cancer.

Do I need extra medical procedures for this study?

No, the tumour sample will be taken during a procedure you are already having, like surgery or a biopsy. You will also provide one small blood sample.

Will the study results change my cancer treatment?

No, the results from the lab tests in this study will not be used to decide your current treatment. Your doctors will continue to follow standard care guidelines.

Can I join if I've had cancer treatment before?

Yes, even if you've been treated for cancer before, or if your cancer has come back or progressed, you might still be able to join.

Is there any cost to me for taking part?

No, there are no costs involved for you to participate in this research study.

How to find out more

Greg Wells, PhD

g.wells@sheffield.ac.uk +44 114 215 9098 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.